{"id":138039,"date":"2026-09-29T13:24:13","date_gmt":"2026-09-29T13:24:13","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/138039\/"},"modified":"2026-09-29T13:24:13","modified_gmt":"2026-09-29T13:24:13","slug":"astrazenecas-2-billion-summit-stake-wins-backing-from-ubs-and-jefferies-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/138039\/","title":{"rendered":"AstraZeneca\u2019s $2 billion Summit stake wins backing from UBS and Jefferies"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/bac656b372010b111755da4ef457df7ff2f560da434bdbe3879df45ce3be93e1\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fproactive_us_504%2F482603a39633900ce4e9e110e6b17a5a.jpg\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"AstraZeneca's $2 billion Summit stake wins backing from UBS and Jefferies\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> AstraZeneca&#8217;s $2 billion Summit stake wins backing from UBS and Jefferies Proactive uses images sourced from Shutterstock           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.proactiveinvestors.com\/companies\/3063\/AstraZeneca-PLC\" data-ylk=\"slk:AstraZeneca%20PLC%20(LSE%3AAZN%2C%20NASDAQ%3AAZN);elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)<\/a>, the FTSE 100 pharmaceutical company, has won positive responses from UBS and Jefferies after investing $2 billion in Summit Therapeutics and agreeing a cancer drug collaboration.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS said the investment gives AstraZeneca exposure to the programmed death-1 and vascular endothelial growth factor (PD-1\/VEGF) class, which combines immune-system activation with inhibition of tumour blood vessel growth.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The broker said emerging evidence suggests the drug class could outperform existing PD-1 treatments in some cancers, making combination data increasingly important if it develops into a new standard of care.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">AstraZeneca will initially test Summit&#8217;s ivonescimab with sonesitatug vedotin, an antibody drug conjugate (ADC) designed to deliver a cancer-killing treatment directly to tumour cells, in gastrointestinal cancers.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Jefferies described the transaction as &#8220;strategically smart&#8221;, saying it gives AstraZeneca a route to combine its oncology ADC portfolio with a PD-1\/VEGF medicine without taking on the risk of a larger acquisition before key clinical results.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The broker said the agreement gives AstraZeneca development flexibility while ensuring it remains involved if the treatment approach is validated globally.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">AstraZeneca will receive rights equivalent to about 12% of Summit&#8217;s outstanding common stock, or 10.6% on a fully diluted basis, while both companies will retain development and commercial rights to their respective medicines.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS said the implied investment price of $18.36 per Summit share represents an 18.6% premium to the company&#8217;s closing price on 28 September. uec96192  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Attention will now turn to Summit&#8217;s HARMONi-3 Phase III trial in first-line metastatic non-small cell lung cancer (NSCLC), with Jefferies expecting the first major readout in the fourth quarter of 2026.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Jefferies maintained a Buy rating on AstraZeneca with a 17,500p price target, while UBS also retained a Buy recommendation with a 15,200p target.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">UBS said AstraZeneca&#8217;s investment was based on publicly available information, with Summit confirming the drugmaker had not received access to undisclosed HARMONi-3 results.  <\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca&#8217;s $2 billion Summit stake wins backing from UBS and Jefferies Proactive uses images sourced from Shutterstock AstraZeneca&hellip;\n","protected":false},"author":2,"featured_media":138040,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[14607,13905,66494,66493,223],"class_list":["post-138039","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-astrazeneca","tag-jefferies","tag-jefferies-proactive","tag-summit-therapeutics","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117354552508604048","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/138039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=138039"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/138039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/138040"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=138039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=138039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=138039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}